Physician profile
Daniel Laroche
NPI 1841225786
$74,056.97
in general payments reported to CMS, 2019-2025
28 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $24K · 2021: $13K · 2022: $15K · 2023: $1,786 · 2024: $905 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,766.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $26,038.53 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $19,555.36 | 2019-2021 | |
| Ivantis, INC | $17,847.67 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $2,701.67 | 2020-2025 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Alcon Vision LLC | $2,623.21 | 2022-2025 | Hydrus Microstent, Simbrinza, Clareon |
| Nidek Co., LTD. | $1,500.00 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $721.20 | 2019-2021 | |
| Abbvie INC. | $508.27 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $422.28 | 2021-2023 | Cequa |
| Allergan, INC. | $307.80 | 2019-2021 | |
| New World Medical,INC. | $268.55 | 2021-2025 | Clearpath, Via360, Streamline |
| Bausch & Lomb Americas INC. | $264.43 | 2023-2025 | Vyzulta, Envista Mx60 Iol |
| Carl Zeiss Meditec Cataract Technology INC. | $192.37 | 2023 | |
| Glaukos Corporation | $145.48 | 2019 | |
| Genentech USA, INC. | $125.00 | 2023 | Vabysmo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $122.48 | 2019 | |
| Kala Pharmaceuticals, INC. | $119.32 | 2019 | |
| Gilead Sciences, INC. | $118.71 | 2025 | Livdelzi |
| Pfizer INC. | $108.63 | 2023 | |
| Rxsight INC | $93.84 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $58.01 | 2022-2024 | Tyrvaya |
| Thea Pharma INC. | $48.60 | 2024 | Iyuzeh |
| Carl Zeiss Meditec USA, INC. | $43.92 | 2024 | |
| Amgen INC. | $40.09 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $32.06 | 2024 | Xdemvy |
| Ocular Therapeutix, INC. | $30.09 | 2023-2024 | Dextenza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Laroche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.